Related references
Note: Only part of the references are listed.Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis
Ray S. Lin et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2020)
On Weighted Log-Rank Combination Tests and Companion Cox Model Estimators
Larry F. Leon et al.
STATISTICS IN BIOSCIENCES (2020)
Data maturity and follow-up in time-to-event analyses
Val Gebski et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2018)
Weighted Cox Regression Using the R Package coxphw
Daniela Dunkler et al.
JOURNAL OF STATISTICAL SOFTWARE (2018)
Personalized vaccines for cancer immunotherapy
Ugur Sahin et al.
SCIENCE (2018)
Designing cancer immunotherapy trials with random treatment time-lag effect
Zhenzhen Xu et al.
STATISTICS IN MEDICINE (2018)
Sequential tests for non-proportional hazards data
Matthias Brueckner et al.
LIFETIME DATA ANALYSIS (2017)
Designing therapeutic cancer vaccine trials with delayed treatment effect
Zhenzhen Xu et al.
STATISTICS IN MEDICINE (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results
S. J. Schuster et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Valsamo Anagnostou et al.
CLINICAL CANCER RESEARCH (2017)
A comprehensive review of immunotherapies in prostate cancer
Manuel Caitano Maia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Implementing a Class of Permutation Tests: ThecoinPackage
Torsten Hothorn et al.
Journal of Statistical Software (2015)
Non-parametric estimation of relative risk in survival and associated tests
Samo Wakounig et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2015)
Sample size determination for the weighted log-rank test with the Fleming-Harrington class of weights in cancer vaccine studies
Takahiro Hasegawa
PHARMACEUTICAL STATISTICS (2014)
Evolution of end points for cancer immunotherapy trials
A. Hoos
ANNALS OF ONCOLOGY (2012)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt
Patrick Royston et al.
STATISTICS IN MEDICINE (2011)
Gene selection in microarray survival studies under possibly non-proportional hazards
Daniela Dunkler et al.
BIOINFORMATICS (2010)
Improved Endpoints for Cancer Immunotherapy Trials
Axel Hoos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Recent Advances in Cancer Vaccines: An Overview
Kyogo Itoh et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
Power and sample size calculation for log-rank test with a time lag in treatment effect
Daomen Zhang et al.
STATISTICS IN MEDICINE (2009)
The estimation of average hazard ratios by weighted Cox regression
Michael Schemper et al.
STATISTICS IN MEDICINE (2009)
Comparing two survival time distributions: An investigation of several weight functions for the weighted logrank statistic
T. Gaugler et al.
COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION (2007)
Share Paper
